Non–Genotype 1 HCV Now and in the Near Future

In this downloadable slideset, Jordan J. Feld, MD, MPH, and Andrew J. Muir, MD, review current and emerging regimens for treating patients with genotype 2, 3, 4, 5, or 6 HCV infection.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.46 MB
Released: June 9, 2016


Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Bristol-Myers Squibb
Gilead Sciences
Janssen Therapeutics
Merck & Co., Inc.
ViiV Healthcare

Related Content

Review key slides on the interplay of COVID-19 and viral hepatitis and review expert strategies for managing chronic liver disease in the COVID-19 era

Released: January 10, 2022

Clinical Care Options (CCO) and Dr. Robert Gish: Interplay of COVID-19 and viral hepatitis, expert strategies for chronic liver disease in the COVID era

Robert G. Gish, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: January 10, 2022 Expired: January 9, 2023

Limitations of the APASL guidelines and potential role of using HBcrAg for treatment candidacy and HCC screening, from Clinical Care Options (CCO)

Yasuhito Tanaka, MD, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 3, 2022 Expired: January 2, 2023

Clinical Care Options (CCO) expert analysis by Dr. Nancy Reau on new viral hepatitis data from AASLD 2021, including HBV, HCV, and hepatitis delta

Nancy Reau, MD Released: December 3, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings